IAG’s Team will Attend ICR Biotech-Investor Conference

Meet IAG’s Bio-Partnering Team at Jefferies Virtual Healthcare Conference, 2020

IAG’s team will be attending ICR Conference 2021 – 11-15th January 2021!

One of the largest investment conferences of the year, the ICR Conference brings the investment community together for presentations by more than 200 public and private companies. Historically consumer focused, this year’s presenters span a broader range of sectors including healthcare, technology, and real estate.

IAG’s Bio-Partnering team is focusing on building a diversified portfolio of innovative life science companies at various stages of clinical development.

‘We are building partnerships, not just seeking business deals, with the goal to improve the quality of life for patients and maximize benefit in society’, said Dr. Olga Kubassova, CEO of IAG.

At IAG, we support novel drug or technology development efforts through conceptualisation, clinical trials to market entry by bringing strategic collaborators and smart investments.

We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immuno-oncology, oncology, inflammation, rheumatology, musculoskeletal, rare diseases, neuro-degenerative and immunology markets.

More on our recent partnerships can be found here: http://www.ia-grp.com/trial-solutions/bio-partnering/

 

About IAG, Image Analysis Group

Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. www.ia-grp.com

 

Engage with our team

Dr. Olga Kubassova, CEO: www.linkedin.com/in/olgakubassova/

David Chia, CCO: https://www.linkedin.com/in/jahyungdavidchia/

Dr. Diana Dupont-Roettger, Chief Scientific Alliance Officer: https://www.linkedin.com/in/dianaroettger/

News
Events